BiotechTube
Alpha-O Peptides

Alpha-O Peptides

Zurich, Switzerland· Est.
aopeptides.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $6.4M

Overview

Alpha-O Peptides AG is a private Swiss biotech firm specializing in the development of advanced vaccine and drug delivery platforms centered on Self-Assembling Protein Nanoparticles (SAPN). The company has built a robust patent estate with filings in major global markets, protecting its core technologies for antigen display, vaccine applications, and immunostimulatory delivery. Its business model revolves around technology development and out-licensing to pharmaceutical and biotechnology partners for further clinical development and commercialization.

Infectious DiseasesOncology

Technology Platform

Proprietary Self-Assembling Protein Nanoparticle (SAPN) technology for designing nanoscale protein structures used as versatile platforms for vaccine antigen display, integrated adjuvant delivery, and encapsulation of immunostimulatory nucleic acids.

Funding History

2
Total raised:$6.4M
Seed$3.2M
Seed$3.2M

Opportunities

The company's modular SAPN platform presents significant opportunities in next-generation vaccine development, particularly for difficult-to-target pathogens and in therapeutic oncology.
The integration of adjuvant functions and nucleic acid delivery within a single nanoparticle could address key unmet needs in vaccine stability, potency, and rapid response capability, making it attractive for partnership.

Risk Factors

Key risks include the pre-clinical nature of all technology, requiring significant validation; reliance on a licensing business model without guaranteed partners; intense competition from large pharma and well-funded biotechs; and the ongoing need for financing to sustain operations and advance the platform.

Competitive Landscape

Alpha-O Peptides competes with large vaccine developers (GSK, Merck) with proprietary adjuvant systems and numerous biotech platform companies (e.g., Vaxxinity, IMV Inc.). Its differentiation hinges on the unique combination of self-assembly, built-in adjuvant activity (flagellin), and nucleic acid encapsulation within a single, protein-based nanoparticle platform protected by a broad patent portfolio.

More companies in Biologics / Biosimilars →More companies in Switzerland →